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Background: The tumor microenvironment plays an important
role in the progression of cancer and may be regulated by prote-
olysis, including the proteasomes. The proteasomes modify the
biologically important molecules involved in the pathogenesis
and progression of a variety of malignancies, including breast
cancer (BC). The aim of this study was to investigate the features
of the subunit composition of proteasomes in the tumor and its
microenvironment of breast cancer.
Material and Methods: Thematerial for investigation was sam-
ples of tumor tissue of invasive ductal breast cancer. The study
was conducted to estimate the distribution of the total pool of
proteasome, proteasomes activator PA700, immune proteasome
forms containing LMP7 and/or LMP2 subunit in tumor cells and
stromal component using immunofluorescence. Furthermore,
there was evaluated the distribution of the proteasome in the
tumor. The expression of immune proteasomes and proteasomes
activators in the cells was studied by immunofluorescence label-
ing of the cells by antibodies to immune proteasome subunits and
cell markers. Fluorescence was analyzed by using a fluorescence
microscope DM RXA2 (‘‘Leica”, Germany) and confocal micro-
scope TCS SP (‘‘Leica”, Germany). The specificity of the primary
antibodies was confirmed by check samples, at which the
reaction was carried out only with the second antibody. No cross
reaction between the first and second antibodies was tested by
incubation of each primary antibodies with the opposing second
antibodies. In addition, there was carried out labeling the cell
nuclei by reagent Hoechst 33,342.
Results: It was found that the tumor cells comprise immune
proteasomes, also PA700 and PA28ab activators. Activator PA28ab
and immune proteasomes are localized in the cytoplasm of tumor
cells, whereas a1, 2, 3, 5, 6, 7 subunits and PA700 activator
detected in the cytoplasm and in the nuclei of tumor cells. Avail-
ability of a1, 2, 3, 5, 6, 7 subunits in the nuclei of tumor cells shows
the expression of constitutive proteasome subunits. Stromal cells
are characterized by a high ratio of the a1, 2, 3, 5, 6, 7 subunits to
the immune LMP2 subunit as compared to cells of invasive ductal
carcinoma. This means that the pool of proteasome in tumor cells
of invasive ductal cancer is enriched by the immune proteasomes
as compared to stromal cells. Thus, samples of invasive ductal
breast cancer contain predominantly tumor cells enriched by
immune proteasomes, activators PA700 and PA28ab. The presence
of proteasomes in stromal component indicates that the tumor
microenvironment also has active processes of proteolysis, with
involving proteasome system. Probably the processes occurring
in the stromal component contribute to the output of the
proteasome into the extracellular space, which is confirmed by
other researchers about the existence of circulating proteasome
pools and their further participation in dissemination of cancer.
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Background: Metformin is a antidiabetic drug with anticancer
properties. However, the mechanism action by which metformin
affects various cancer cells still unknown. It is known that tumor
growth is accompanied by changes in the metabolic cascade that
includes overproduction of lactate and adenosine. The adenosine
is released into the extracellular environment and regulates
differentiation, proliferation, and angiogenesis of tumor mass.
We found that lactate is activator of key enzyme of adenosine
metabolism – adenosine deaminase (ADA).
Aim: The aim of our study was to investigate the catabolism of
adenosine in the tumor while taking metformin.
Materials and methods: In this study we investigated the level
of adenosine, inosine, hypoxanthine and ADA activity in 15
women aged 46–76 years, with breast cancer (BC) T2-4N1M0 (can-
cer tissues) during treatment with metformin, 1000 mg per day
for 3 months. Control group – 15 women aged 46–76 years, with
stage T2-4N1M0 breast cancer (cancer tissues) without metformin
therapy.
Statistical analysis was performed using the license package
StatSoft. Statistica 12.0.
Results: ADA activity during treatment with metformin was 2-
fold increased: 12.1 ± 2.49 nmol/min*mg in comparison with 4.77
± 0.943 nmol/min*mg. Concentration of catabolic products of ade-
nosine degradation was increased before metformin therapy. Ino-
sine level was 0.121 ± 0.041 micro mol/g tissue (BC tissues from
women without metformin 0.042 ± 0.015 micro mol/g tissue).
Hypoxanthine 2.45 ± 0.428 micro mol/g tissue (in comparison
with 0.711 ± 0.269 micro mol/g tissue). Whereas, adenosine level
in BC after metformin therapy was 0.226 ± 0.148 micro mol/g tis-
sue (in comparison with 0.186 ± 0.056 micro mol/g tissue), that
were not significantly different.
50 EJC SUPPLEMENTS 13 (2015) 1–75
